Brain Cancer related Tumor Profiling Service
Creative Biolabs, your useful helper in brain cancer study.
Tumor profiling has transformed brain cancer research by identifying key biomarkers like CD133, nestin, and UCH-L1, offering insights into tumor heterogeneity, progression, and resistance. Despite challenges like the blood-brain barrier, Creative Biolabs overcame these with multi-omics integration and constructed our Tumor Profiling to Guide Targeted Cancer Therapy Platforms. Our services empower researchers to make informed decisions, driving innovation in brain cancer research.
Introduction of Tumor Profiling in Brain Cancer
Brain tumors, especially gliomas, rank among the most aggressive neoplasms in the central nervous system (CNS). Glioblastoma multiforme (GBM) is notorious for its malignancy and therapeutic resistance. The blood-brain barrier, along with the heterogeneity depicted in Fig. 1, further complicates diagnosis and treatment. Despite progress in imaging and multimodal treatments, effective management remains challenging due to tumor heterogeneity and therapeutic resistance. Appropriate and comprehensive tumor profiling could help improve the effectiveness of personalized immunotherapy.
Tumor profiling offers critical insights into the molecular landscape of brain cancer, helping uncover diagnostic biomarkers, therapeutic targets, and resistance mechanisms. As a leading expert in biological research, Creative Biolabs provides advanced solutions for tumor profiling that assist in addressing the complexities of brain tumors through innovative molecular and proteomic approaches.
Precision Brain Tumor Profiling
Creative Biolabs has established advanced platforms to support your oncology research.
Recent advances in technologies and biomarkers for tumor profiling have provided us insight into the heterogeneity among brain tumor cells, supporting prognosis and precise treatment development and leading to future research improvement of brain cancer. Creative Biolabs provides brain tumor profiling in different biomarker expression levels with different techniques. We provide a table detailing the technologies and biomarker panels for profiling 10 different cancers, such as brain cancer, breast cancer, non-small cell lung cancer, and colorectal cancer. You can get specific information for any type of tumor that you are interested in. These technologies and biomarkers include but are not limited to:
| Well-studied Biomarkers | ||||
|---|---|---|---|---|
| Technologies | Genetic | Chromosomal | Transcriptional | Proteomic |
| Brain Cancer | ||||
|
NGS ISH PCR IHC Microarray |
EGFR TP53 IDH1 EPHB2 APC MYC MLHI BAP1 SMAD4 COL4A1 ERBB2 HRAS AKT1 CDKN2B EPCAM |
CDKN2A(p16) deletion EGFR amplification MET amplification CDKN2A (p16) deletion |
ALK RAF1 BRAF ROS1 EGFR FGFR1 |
GFAP S100B |
| Breast Cancer | ||||
|
NGS ISH PCR IHC Microarray |
BRAF TP53 EGFR BRCA1/2 KRAS ERBB2/4 CDH1 MET CDK12 PTEN FGFR1/2/3 HRAS CHEK1/2 PIK3CA ATM |
MET PTEN |
HER2 ER PR |
PD-L1 22C3 Pan-TRK |
| Non-Small Cell Lung Cancer (NSCLC) | ||||
|
NGS FISH PCR IHC Microarray FC IF |
STK11 AKT1 EGFR BRAF KRAS ERBB2/4 TP53 MET FGFR1/2/3 CCND1 PTEN HRAS RB1 PIKЗCA ATM |
ALK MET PTEN RET |
VEGFA |
PD-L1 HER2 Pan-TRK |
| Colorectal Cancer | ||||
|
NGS FISH IHC FC LC-MS |
ALK AKT1 EGFR BRAF KRAS ERBB2/4 TP53 MET FGFR1/2/3 NOTCH1 PTEN ROS1 RB1 PIK3CA ATM |
ALK MET PTEN RET ROS1 |
PD-L1 |
PD-L1 HER2 Pan-TRK |
| Melanoma Cancer | ||||
|
NGS FISH PCR IHC Microarray FC |
AKT1 EGFR BRAF ERBB2/4 FGFR1/2/3 MET PDFFRA NRAS KIT CDK4 |
PTEN | MITF |
PD-L1 Pan-TRK |
| Pancreatic Cancer | ||||
|
NGS FISH PCR IHC Microarray |
Gene Variations KRAS TP53 SMAD4 CDKN2A RREB1 KDM6A RAC1 ARMET BRAF TGFBR2 ACVR1B MAP3K21 RAS ARMET RNF43 |
Chr 1~22 and Chr X, insertions, deletions, duplications, inversions and translocations |
MicroRNAs, Long noncoding RNAs, DNA methylation |
CA 19-9 |
| Ovarian Cancer | ||||
|
NGS FISH PCR IHC Microarray RT-PCR ELISA Whole Transcriptome Sequencing DNA Methylation |
CTNNB1 PRKN TP53 PIKЗCA OPCML AKTI CDH1 ERBB2 RRAS2 PARK2 BRCA1/2 STK11 CDKN2B EPCAM |
hyper- and hypo-methylation: OPCML DCR1 RASSF1A BRCA1 histone modification and miRNAs: Sirtuin-1 TGF |
Cytokines/Chemokines: MFAP2 SEMG2 DLK1 Pro-apoptotic Proteins: NTNG1 CA-125 ILs XCL1 Angiogenic factors: CXCL7 VEGF EGFR ErbB2 |
|
| Endometrial Cancer | ||||
|
NGS FISH PCR IHC Microarray FC IF RT-PCR ELISA |
BRAF PIKЗCA APC BRCA1/2 SMAD4 HRAS TP53 CDH1 EGFR EPCAM KIT PTEN ESR1 MSH2/6 NRAS PDGFRA SMO SMARCA4 ATM FGFR1/2/3 |
MET PTEN |
PD-L1 |
HER2 PDL1 |
| Thyroid Cancer | ||||
|
NGS FISH PCR IHC Microarray |
TP53 KRAS ERBB2/4 ALK ATM BRAF CDKN2A RET PIK3CA SMO CDKN2A PTEN SMAD4 HRAS CTNNB1 |
MET RET |
PD-L1 |
Pan-TRK PD-L1 |
| Head and Neck Cancer | ||||
|
NGS FISH PCR IHC Microarray IF ELISA |
PTEN TP53 PTEN KRAS EGFR CTNNB1 BRAF PIK3CA ERBB2 FGFR1/2/3 CDKN2A NOTCH1 AKT1 RB1 ATM |
MET PTEN RET |
PD-L1 |
Pan-TRK PD-L1 |
Simplified Workflow for Brain Tumor Profiling
If you have any specific requirements for the tumor profiling process, feel free to contact us. Our expert team can customize the profiling services to meet your exact needs.
Get Your Tailored Service Now →
How to Overcome Challenges in Tumor Profiling
Creative Biolabs offers cutting-edge solutions to overcome these obstacles, ensuring that tumor profiling becomes a valuable tool in brain cancer management.
Multi-Omics Integration
By combining proteomics, genomics, and transcriptomics, Creative Biolabs provides a comprehensive approach to tumor profiling. This integration helps uncover novel molecular pathways and improves the accuracy of biomarker discovery.
Single-Cell Profiling Technologies
Advanced single-cell technologies are employed to analyze rare cell populations, such as BTSCs, and understand the dynamics of tumor heterogeneity at the cellular level.
Non-Invasive Biomarker Development
Creative Biolabs focuses on liquid biopsy technologies, which aim to detect brain tumor biomarkers in blood and CSF. This approach offers a less invasive alternative for disease monitoring and early detection.
Validation Platforms for Clinical Translation
We provide comprehensive biomarker validation platforms, ensuring the clinical applicability of identified biomarkers. This facilitates the translation of research findings into reliable diagnostic and therapeutic tools.
Why Choose Us?
Creative Biolabs stands at the forefront of tumor profiling solutions for brain cancer, offering a wide range of services designed to enhance research and clinical outcomes. We have:
Advanced Molecular Profiling
Utilizing state-of-the-art technologies, we provide comprehensive molecular profiling services, including genomic, proteomic, and transcriptomic analyses.
Biomarker Discovery and Validation
We specialize in identifying novel biomarkers through high-throughput screening and validating them using rigorous clinical protocols.
Custom Bioinformatics Support
Our team of bioinformatics experts offers tailored data analysis solutions, helping researchers interpret complex molecular data and derive actionable insights.
Collaborative Research and Development
At Creative Biolabs, we actively collaborate with academic and clinical partners to accelerate biomarker discovery and develop new therapeutic strategies.
Come and get your customized brain tumor profiling service!
Ready to Get an Instant Quote?
Trust Creative Biolabs to deliver tailored solutions, offering precise and actionable insights to support every step of your immuno-oncology research journey.
Creative Biolabs provided exceptional insights into brain cancer research through their tumor profiling platform. Their multi-omics integration and biomarker identification gave us clarity on tumor heterogeneity, aiding in personalized therapies and overcoming research challenges.
—Dr. Alan H., Oncology Researcher
We collaborated with Creative Biolabs for brain tumor profiling, and their advanced genomic and proteomic analyses identified critical biomarkers like CD133 and EGFR. Their comprehensive reports enabled us to refine treatment strategies with precision.
—Sarah M., Neuroscientist
Their tailored tumor profiling services provided clarity on therapeutic resistance in glioblastoma, optimizing our research pipeline. The seamless communication and collaborative approach were instrumental in aligning our clinical strategies.
—Emily J., Research Coordinator